# Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults

> **NCT04227210** · PHASE1 · COMPLETED · sponsor: **Meissa Vaccines, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** RSV vaccine MV-012-968 (dosage #1)
- **BIOLOGICAL:** RSV vaccine MV-012-968 (dosage #2)

## Key facts

- **NCT ID:** NCT04227210
- **Lead sponsor:** Meissa Vaccines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-14
- **Primary completion:** 2020-08-27
- **Final completion:** 2020-08-27
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04227210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04227210, "Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04227210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*